

Iliya Amaza*, MD, MPH
Aleksandra Zgierska*, MD, PhD
Michael F Fleming†, MD, MPH

2013 Wisconsin Health Improvement & Research Partnership Forum September 12, 2013

*Department of Family Medicine, University of Wisconsin School of Medicine and Public Health
† Department of Family Medicine, Northwestern University, Chicago, IL

Disclosure

The authors have nothing to disclose

& have no actual or potential conflict of

interest in relation to this presentation

Drug SBIRT: Outline

- Rationale
- The Basics
- Professional Recommendations
- Evidence
- Clinical Approach
- Conclusions
- Discussion


Rationale...

- Among Americans ≥ 12 years old:
 - 22.5 million people reported past month illicit drug use

6.5 million have a drug (± alcohol) addiction

Rationale...

7.2 million Americans need treatment for illicit drug use:



5.8 million need but do not receive services

Why Primary Care?

- Extensive number & variety of patients¹
- Adults with drug use disorders are overrepresented²
- Focus on prevention¹
- Longitudinal, trusting patient-clinician relationships¹

- I. Saitz R, et al. | Addict Med. 2010;4(3):123-130.
- 2. Pilowsky DJ, Wu LT. Subst Abuse Rehabil. 2012;3(1):25-34.

Rationale...

- Societal costs
 - \$193 billion yearly (2010)
- Associated with negative consequences
 - Medical
 - Social
 - Legal






SBIRT

a comprehensive, integrated, public-health approach to the identification and delivery of early intervention services for individuals with unhealthy substance use

SBIRT Basics



Alcohol & Tobacco SBIRT

- SBIRT: documented efficacy for

 - Tobacco Cessation
 (USPSTF Grade A, 2009)
 high certainty of substantial net benefit

"Prescription drug abuse is the Nation's fastest growing drug problem"

- Office of National Drug Control Policy (2011)

Professional Recommendations


- AMA (2010): "screening for... drug use in a variety of settings"
- **AAFP** (2009): "diagnose substance abuse and addiction in the earliest stage possible, and treat or refer for treatment"
- **AAP (2011)**: "screening all adolescent patients... at every contact, and initiating BI and RT when appropriate"
- ACOG & ASAM (2012): opioid screening part of "complete obstetric care"
- APA (2012): "a routine part of medical assessment"
- NIH-NIDA (2012), SAMHSA (2012)

Existing Evidence

- 3 randomized controlled trials that included <u>universal</u> screening as a part of the SBI approach
- Heterogeneity of study methods, including the drugs of focus and assessment tools, precluded data pooling and meta-analysis

Cocaine & Heroin: Bernstein et al, 2005*


23,699 adult cocaine and/or heroin users from urgent care, women's health & homeless clinics



^{*} Bernstein J, et al. Drug Alcohol Depend. 2005;77(1):49-59.

Prescription Drugs: Zahradnik et al, 2009*

6042 general hospital adult inpatients using addictive prescription drugs




^{*} Zahradnik A, et al. Addiction. 2009;104(1):109-117.

Illicit Drugs: Humeniuk et al, 2012*

Primary care patients in Australia, Brazil, India, U.S.



731 eligible & enrolled



Follow up at 3 months



Reduction in Substance Involvement scores more in BI than controls

^{*} Humeniuk R, et al. Addiction. 2012;107(5):957-966.


Humeniuk et al, 2012: Illicit Drugs in Primary Care Settings

| | Australia (N = 171) | Brazil (N = 165) | India (N = 177) | U.S. (N =218) |
|------------|------------------------|---------------------|--------------------|-------------------|
| All | 1 | ↓ | 4 | \leftrightarrow |
| Cannabis | \leftrightarrow | \ | 4 | \leftrightarrow |
| Stimulants | \ | \ | N/A | \leftrightarrow |
| Opioids | N/A | N/A | \ | N/A |
| | | | | |

USPSTF Summary of Evidence

"the current evidence is insufficient to assess the balance of benefits and harms of screening adolescents, adults, and pregnant women for illicit drug use" in primary care settings (2008)

Clinical Approach: Drug SBIRT



- National Institute on Drug Abuse (NIDA)
- Revised: March 2012
- Addresses all forms of substance use
- http://www.drugabus
 e.gov/publications/res
 ource-guide

Clinical Approach: Setting the Stage

- Who does what?
- Incorporate SBI into current workflow
- Obtain reimbursement information
- Establish referral linkages
- Anticipate challenges
- Identify appropriate screening and assessment tools

Clinical Approach: Ask

| Step 1 (ASK): In the past year, how often have you used the following? (positive screen) | Never | positive initial screen (detailed assessment) | | | | |
|---|-------|---|--|--|--|--|
| Alcohol (heavy drinking) | | "Yes": Proceed with the NIAAA Clinician's Guide recommended assessment | | | | |
| Tobacco Products (any use) | | "Yes": Proceed with the "Helping Smokers Quit" recommendations | | | | |
| Prescription Drugs for Non- Medical Reasons (any use) Illegal Drugs (any use) | | "Yes": Proceed with the NIDA recommended assessment (NIDA-Modified ASSIST survey) | | | | |
| "Never" response to all Step 1 questions: negative screen. Praise and reinforce. SBI is completed. | | | | | | |

Adapted from the NIDA Resource Guide (2012)

Clinical Approach: Ask


| Step 1 | Step 2 | Step 3 | Step 4 |
|---|----------------------------|---|----------------------|
| (Screen) | (Assessment) | | (Brief Intervention) |
| Yes to nonmedical prescription drugs use or illegal drug use? | | Determine risk level with Substance Involvement score | ADVISE |
| Cocaine | ST | | |
| Cannabis | Begin NIDA-Modified ASSIST | HIGH RISK Score ≥ 27 | |
| Hallucinogens | fied | | ASSESS |
| Inhalants | odiy | | |
| Methamphetamine | M-W | MODERATE RISK Score 4 - 26 | |
| Sedatives | NII | Score 4 - 20 | ASSIST |
| Street opioids | gin | | |
| Prescription amphetamines | Be | LOW RISK Score 0 - 3 | |
| Prescription opioids | | | ARRANGE |

Adapted from the NIDA Resource Guide (2012)

Clinical Approach: Advise

- Direct, non-judgmental personal advice about substance use
- Give specific reasons for quitting or cutting down

Public Health: Harm Reduction Paradigm



Amount of substance used

Clinical Approach: Advise

- Offer HIV + STI screening to sexually active patients. Encourage safe sex.
- Offer HIV and Hepatitis B/C testing for positive history of injection drug use
- Refer for evaluation of suspected cooccurring conditions

Clinical Approach: Assess

Not ready

- Reaffirm the consequences of drug use
- Restate willingness to help when ready.
- Revisit the issue at subsequent visits.

Ready

 Reinforce current efforts. Assist in making changes.

Clinical Approach: Assist


- Jointly create a follow up plan
- Help set concrete and reasonable goals for making a change
- Prescribe addiction treatment medications as appropriate

Clinical Approach: Arrange

- Refer patients as appropriate
- If no nearby treatment, provide support group information and counseling resources
- Schedule follow up appointment
- Offer continuing support at follow up visits

Issues to Consider

- Sparse evidence yet widely endorsed
- Which screening tools to choose?
- Multiple drug use





Issues to Consider

- Accessibility: insurance, geographic
- Confidentiality/Stigma
- Provider: comfort level, time pressure
- Resources
 - SAMHSA's Treatment Services Locator: <u>http://findtreatment.samhsa.gov</u>
 - NIDA's List of Community Treatment Programs: www.drugabuse.gov/CTN/ctps.html
 - Buprenorphine Web-Based Training
 http://buprenorphine.samhsa.gov/training main.html

What about Marijuana?

 Legal in 21 U.S. states & D.C.
 Considered illicit by the Federal Government

• AAFP (2009): "opposes the recreational use of marijuana. With regards to the medical use of marijuana, the AAFP defers to all applicable federal and state laws..."

• ASAM (2012): "...opposes proposals to legalize marijuana... The analyses on the possible outcomes—both intended and unintended—of the state-based... proposals... suggest that risks are unacceptable."



Conclusions

- Evidence for drug SBI is growing, but still inconclusive
- Recommended as an approach to halting drug use
- Need for brief, validated tools
- More research is needed

Thank You!

iliya.amaza@fammed.wisc.edu aleksandra.zgierska@fammed.wisc.edu


Other Resources

- NM-ASSIST: <u>www.drugabuse.gov/nmassist</u>
- Helping Patients Who Drink Too Much: A Clinician's Guide <u>http://www.niaaa.nih.gov/publications/clinical-guides-and-manuals/niaaa-clinicians-guide-online-training</u>
- Helping Smokers Quit: A Guide for Clinicians: http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/references/clinhlpsmkqt/
- Coding for SBI Reimbursement
 <u>http://www.samhsa.gov/prevention/sbirt/coding.aspx</u>
- Role of the physician in "medical marijuana" http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2011/11/28/the-role-of-the-physician-in-medical-marijuana

Acknowledgements

Aleksandra Zgierska, MD, PhD
Mike Fleming, MD, MPH
Richard Brown, MD, MPH
Marlon Mundt, PhD
Barbara Duerst, MS
UW MPH program

Why Do People Change?



Fisher & Fisher, 1992, 2000

Five Principles of MI

- Roll with Resistance
 - with reflection, reframing, redirection
- Express Empathy
 - through reflective listening
- Avoid Argumentation
 - or direct confrontations
- Develop Discrepancy
 - between goals and behavior
- Support Self-efficacy
 - optimism, ability to make changes

SBI in Youth: Statement

USPSTF (2008)

"the current evidence is insufficient to assess the balance of benefits and harms of screening <u>adolescents</u>, adults, and pregnant women for illicit drug use" in primary care settings

SBI in Youth: Recommendations

- **AAP** (2011): "screening <u>all adolescent</u> patients... at <u>every contact</u>, and initiating BI and RT when appropriate"
- **APA** (2009): "psychiatrists should support treatment for <u>adolescents</u> with substance use problems by appropriate screening, diagnosis, treatment, referral and coordination of care"

SBI in Youth: Issues

- What age to start screening?
- Confidentiality
- Parental involvement
- Resource
 - Center for Adolescent Health and the Law (<u>www.cahl.org</u>)

